NCT06730230 Partners in Control, Phase II: Using Remote Monitoring Technology With Community Health Workers to Support Hypertension Management for Latinx Patients
| NCT ID | NCT06730230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-02-10 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-02-10 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to evaluate the impact of a remote patient monitoring (RPM)-specific tech-enabled community health worker workforce on the use of RPM for the management of hypertension among Latinx patients. This study is a step-wedge randomized controlled trial that aims to assess the effectiveness and implementation of RPM-enabled community health workers (CHWs) compared to standard of care RPM hypertension management on blood pressure reduction and evaluate the implementation of the RPM-enabled CHWs for hypertension (HTN) management. The study aims to examine adoption, acceptability, fidelity, cost, sustainability, and equity as outcomes of implementation effectiveness.
Eligibility Criteria
Inclusion Criteria: 1. Self-identify as Latinx 2. Be fluent in English or Spanish 3. Be age 18 years or older 4. Receiving care at one of the 10 safety-net primary care clinics 5. Have uncontrolled HTN documented in the electronic health record (EHR) on at least two visits in the past year (defined as an average BP ≥ 140/90 mmHg) 6. Have been prescribed at least one anti-hypertensive medication and be non-adherent to their medications, defined as adherence \<80% in the preceding 12 months, as determined by prescription orders obtained from the clinic EHR. Exclusion Criteria: 1. Being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks) 2. Participation in other hypertension-related clinical trials 3. Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR) 4. Plan to discontinue care at the clinic within the next 15 months
Contact & Investigator
Devin Mann, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06730230 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06730230 currently recruiting?
Yes, NCT06730230 is actively recruiting participants. Contact the research team at Devin.Mann@nyulangone.org for enrollment information.
Where is the NCT06730230 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06730230 clinical trial?
NCT06730230 is sponsored by NYU Langone Health. The principal investigator is Devin Mann, MD at NYU Langone Health. The trial plans to enroll 300 participants.